Differentially expressed genes in androgen-dependent and -independent prostate carcinomas

Cancer Research

Volumn 57, Issue 18, 1997, Pages 4075-4081

  Chang, Glenn T G ^a   Blok, Leen J ^a   Steenbeek, Martine ^a   Veldscholte, Jos ^a,b   Van Weerden, Wytske M ^a   Van Steenbrugge, Gert J ^a   Brinkmann, Albert O ^a  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN;

ARTICLE; CANCER GROWTH; GENE EXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CARCINOMA; SEQUENCE ANALYSIS; XENOGRAFT;

ANDROGENS; ANIMALS; BASE SEQUENCE; CALCITRIOL; CELL CYCLE; CELL DIVISION; CLONING, MOLECULAR; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCURONOSYLTRANSFERASE; HUMANS; MALE; METRIBOLONE; MICE; MICE, NUDE; MOLECULAR SEQUENCE DATA; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; PROSTATIC NEOPLASMS; RNA, MESSENGER; RNA, NEOPLASM; TRANSCRIPTION FACTORS; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0030773168     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (63)

1. Coffey, D. S. Prostate cancer: an overview of an increasing dilemma. Cancer (Phila.), 71: 880-886, 1993.
2. Carter, H. B., and Coffey, D. S. The prostate: an increasing medical problem. Prostate, 16: 39-48, 1990.
3. Huggins, C., and Hodges, C. V. Studies on prostate cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res., 1: 293-297, 1941.
4. Isaacs, J. T., and Coffey, D. S. Adaption versus selection as the mechanism responsible for the relapse to prostatic cancer to androgen ablation therapy as studied in Dunning R-3327-H adenocarcinoma. Cancer Res., 41: 5070-5075, 1981.
5. Rinker-Schaeffer, C. W., Partin, A. W., Isaacs, W. B., Coffey, D. S., and Isaacs, J. T. Molecular and cellular changes associated with the acquisition of metastatic ability by prostatic cancer cells. Prostate, 25: 249-265, 1994.
6. Fearon, E. R., and Vogelstein, B. A genetic model for colorectal tumorigenesis. Cell, 61: 759-767, 1990.
7. Knudson, A. G. All in the (cancer) family. Nat. Genet., 5: 103-104, 1993.
8. McDonnell, T. J., Troncoso, P., and Brisby, S. M. Expression of the proto-oncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res., 52: 6940-6944, 1992.
9. Sun, Y., Lin, J., Katz, A. E., and Fisher, P. B. Human prostatic carcinoma oncogene PTI-1 is expressed in human tumor cell lines and prostate carcinoma patient blood samples. Cancer Res., 57: 18-23, 1997.
10. Smith, J. R., Freije, D., Carpten, J. D., Grönberg, H., Xu, J., Isaacs, S. D., Brownstein, M. J., Bova, G. S., Guo, H., Bujnovszky, P., Nusskern, D. R., Damber, J. E., Bergh, A., Emanuelsson, M., Kallioniemi, O. P., Walker-Daniels, J., Bailey-Wilson, J. E., Beaty, T. H., Meyers, D. A., Walsh, P. C., Collins, F. S., Trent, J. M., and Isaacs, W. B. Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science (Washington DC), 274: 1371-1374, 1996.
11. Bookstein, R., Rio, P., Madreperla, S. A., Hong, F., Allred, C., Grizzle, W. E., and Lee, W. H. Promoter deletion and loss of retinoblastoma expression in human prostate carcinoma. Proc. Natl. Acad. Sci. USA, 87: 7762-7766, 1990.
12. Kubota, Y., Fujinami, K., Uemura, H., Dobashi, Y., Miyamoto, H., Iwasaki, Y., Kitamura, H., and Shuin, T. Retinoblastoma gene mutations in primary human prostate cancer. Prostate, 27: 314-320, 1995.
13. Visakorpi, T., Kallioniemi, O. P., Heikkinen, A., Koivula, T., and Isola, J. Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. J. Natl. Cancer Inst., 84: 883-887, 1992.
14. Navone, N. M., Troncoso, P., Pisters, L. L., Goodrow, T. L., Palmer, J. L., Nichols, W. W., Von Eschenbach, A. C., and Conti, C. p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J. Natl. Cancer Inst., 85: 1657-1669, 1993.
15. Bookstein, R., MacGrogan, D., Hilsenbeck, S. G., Sharkey, F., and Allred, D. C. p53 is mutated in a subset of advanced-stage prostate cancer. Cancer Res., 53: 3369-3373, 1993.
16. Dinjens, W. N., van der Weiden, M. M., Schröder, F. H., Bosman, F. T., and Trapman, J. Frequency and characterization of p53 mutations in primary and metastatic human prostate cancer. Int. J. Cancer, 56: 630-633, 1994.
17. Brooks, J. D., Bova, G. S., Ewing, C. M., Pianadosi, S., Carter, B. S., Robinson, J. C., Epstein, J. I., and Isaacs, W. B. An uncertain role for p53 gene alterations in human prostate cancer. Cancer Res., 56: 3814-3822, 1996.
18. Zervos, A. S., Gyuris, J., and Brent, R. Mxi1, a protein that specifically interacts with Max to bind Myc-Max recognition sites. Cell, 72: 223-232, 1993.
19. Eagle, L. R., Yin, X., Brothman, A. R., Williams, B. J., Atkin, N. B., and Prochownik, E. V. Mutations of the MXI1 gene in prostate cancer. Nat. Genet., 9: 249-255, 1995.
20. Sheng, S., Carey, J., Seftor, E. A., Dias, L., Hendrix, M. J., and Sager, R. Maspin acts at the cell membrane to inhibit invasion and motility of mammary and prostatic cancer cells. Proc. Natl. Acad. Sci. USA, 93: 11669-11674, 1996.
21. Dong, J. T., Lamb, P. W., Rinker-Schaeffer, C. W., Vukanovic, J., Ichikawa, T., Isaacs, J. T., and Barrett, J. C. KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. Science (Washington DC), 268: 884-886, 1995.
22. Carter, B. S., Ewing, C. M., Ward, W. S., Treiger, B. F., Aalders, T. W., Schalken, J. A., Epstein, J. I., and Isaacs, W. B. Allelic loss of chromosomes 10q and 16q in human prostate cancer. Proc. Natl. Acad. Sci. USA, 87: 8751-8755, 1990.
23. Bergerheim, U. S. R., Kumini, K., Collins, V. P., and Eckman, P. Deletion mapping of chromosomes 8, 10 and 16 in human prostatic carcinoma. Genes Chromosomes Cancer, 3: 215-220, 1991.
24. Bova, G. S., Carter, B. S., Bussemakers, M. J. G., Emi, M., Fujiwara, Y., Kyprianou, N., Jacobs, S. C., Robinson, J. C., Epstein, J. I., Walsh, P. C., and Isaacs, W. B. Homozygous deletion and frequent allelic loss of chromosome 8p22 loci in human prostate cancer. Cancer Res., 53: 3869-3873, 1993.
25. Trapman, J., Sleddens, H. F. B. M., van der Weiden, M. N., Dinjens, W. N. M., Konig, J. J., Santerse, B., Schröder, F. H., Faber, P. W., and Bosman, F. T. Loss of heterozygosity of chromosome 8 microsatellite loci implicates a candidate tumor suppressor gene between loci D8S87 and D8S133 in human prostate cancer. Cancer Res., 54: 6061-6064, 1994.
26. Visakorpi, T., Kallioniemi, A. H., Syvänen, A. C., Hyytinen, E. R., Karhu, R., Tammela, T., Isola, J. J., and Kallioniemi, O. P. Genetic changes in primary and recurrent prostate cancer by comparative genomic hybridization. Cancer Res., 55: 342-347, 1995.
27. Cher, M. L., Bova, G. S., Moore, D. H., Small, E. J., Carroll, P. R., Pin, S. S., Epstein, J. I., Isaacs, W. B., and Jensen, R. H. Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping. Cancer Res., 56: 3091-3102, 1996.
28. Horoszewics, J. S., Leong, S. S., Chu, T. M., Wajsman, Z. L., Friedman, M., Papsidero, L., Kim, U., Chai, L. S., Kakati, S., Arya, S. K., and Sandberg, A. A. The LNCaP cell line - A new model for studies on human prostatic carcinoma. In: G. P. Murphy (ed.), Models for Prostate Cancer, pp. 115-132. New York: Alan R. Liss, Inc., 1980.
29. Horoszewics, J. S., Leong, S. S., Kawinski, E., Karr, J. P., Rosenthal, H., Chu, T. M., Mirand, E. A., and Murphy, G. P. LNCaP model of human prostatic carcinoma. Cancer Res., 43: 1809-1818, 1983.
30. van Steenbrugge, G. J., van Uffelen, C. J., Bolt, J., and Schröder, F. H. The human prostatic cancer cell line LNCaP and its derived sublines: an in vitro model for the study of androgen sensitivity. J. Steroid Biochem. Mol. Biol., 40: 207-214, 1991.
31. Welsh, J., Chada, K., Dalal, S. S., Cheng, R., Ralph, R., and McCleland, M. Arbitrarily primed PCR fingerprinting of RNA. Nucleic Acids Res., 21: 2627-2631, 1992.
32. Liang, P., and Pardee, A. B. Differential display of eukaryotic messenger RNA by means of the polymerase chain reaction. Science (Washington DC), 257: 967-971, 1992.
33. Hinegardner, R. T. An improved fluorometric assay for DNA. Anal. Biochem., 39: 197-201, 1971.
34. Keyomarsi, K., Sandoval, L., Band, V., and Pardee, A. B. Synchronization of tumor and normal cells from G1 to multiple cell cycles by lovastatin. Cancer Res., 51: 3602-3609, 1991.
35. Jakobisiak, M., Bruno, S., Skierski, J. S., and Darzynkiewicz, Z. Cell cycle-specific effects of lovastatin. Proc. Natl. Acad. Sci. USA, 88: 3628-3632, 1991.
36. Blok, L. J., Grossmann, M. E., Perry, J. E., and Tindall, D. J. Characterization of an early growth response gene, which encodes a zinc finger transcription factor, potentially involved in cell cycle regulation. Mol. Endocrinol., 9: 1610-1620, 1995.
37. Auffray, C., and Rougeon, F. Purification of mouse immunoglobulin heavy-chain messenger RNAs from total myeloma tumor RNA. Eur. J. Biochem., 107: 303-314, 1980.
38. Liang, P., Zhu, W., Zhang, X., Guo, Z., O'Connell, R., Averboukh, L., Wang, F., and Pardee, A. B. Differential display using one-base anchored oligo-dT primers. Nucleic Acids Res., 22: 5763-5764, 1994.
39. Bauer, D., Müller, H., Reich, J., Riedel, H., Ahrenkiel, V., Warthoe, P., and Strauss, M. Identification of differentially expressed mRNA species by an improved display technique (DDRT-PCR). Nucleic Acids Res., 21: 4272-4280, 1993.
40. Zhao, S., Ooi, S. L., and Pardee, A. B. New primer strategy improves precision of differential display. Biotechniques, 18: 842-850, 1995.
41. Sambrook, J., Fritsch, E. F., and Maniatis, T. Molecular Cloning: A Laboratory Manual, Ed. 2, pp. 1.72-1.84. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1989.
42. Feinberg, A. P., and Vogelstein, B. A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. Anal. Biochem., 132: 6-13, 1983.
43. van Steenbrugge, G. J., van Weerden, W. M., de Ridder, C. M. A., van der Kwast, T. H., and Schröder, F. H. Development and application of prostatic xenograft models for the study of human prostate cancer. In: M. Motta and M. Serio (eds.), Sex Hormones and Antihormones in Endocrine Dependent Pathology: Basic and Clinical Aspects, pp. 11-22. Amsterdam: Elsevier Science B. V., 1994.
44. van Weerden, W. M., de Ridder, C. M. A., Verdaasdonk, C. L., Romijn, J. C., van der Kwast, T. H., Schröder, F. H., and van Steenbrugge, G. J. Seven newly developed human prostate tumor xenograft models: establishment and histopathological characterization. Am. J. Pathol., 149: 1055-1062, 1996.
45. Altschul, S. F., Gish, W., Miller, W., Myers, E. W., and Lipman, D. J. Basic local alignment search tool. J. Mol. Biol., 215: 403-410, 1990.
46. Rouault, J. P., Rimokh, R., Tessa, C., Paranhos, G., Ffrench, M., Duret, L., Garoccio, M., Germain, D., Samarut, J., and Magaud, J. P. BTG1, a member of a new family of antiproliferative genes. EMBO J., 11: 1663-1670, 1992.
47. Chen, F., Ritter, J. K., Wang, M. G., McBride, O. W., Lubet, R. A., and Owens, I. S. Characterization of a cloned human dihydrotestosterone/androstenediol UDP-glucuronosyltransferase and its comparison to other steroids isoforms. Biochemistry, 32: 10648-10657, 1993.
48. Yang, M., and Sytkowski, A. J. Cloning differentially expressed genes by linker capture subtraction. Anal. Biochem., 237: 109-114, 1996.
49. Averboukh, L., Liang, P., Kantoff, P. W., and Pardee, A. B. Regulation of S100P expression by androgens. Prostate, 29: 350-355, 1996.
50. Blok, L. J., Kumar, M. V., and Tindall, D. J. Isolation of cDNAs that are differentially expressed between androgen-dependent and androgen-independent prostate carcinoma cells using differential display. Prostate, 26: 213-224, 1995.
51. Tilly, W. D., Wilson, C. M., Marcelli, M., and McPhaul, M. J. Androgen receptor gene expression in human prostate carcinoma cell lines. Cancer Res., 50: 5382-5386, 1990.
52. Young, C. Y. F., Montgomery, B. T., Andrews, P. E., Qiu, S., Bilhartz, D. L., and Tindall, D. J. Hormonal regulation of prostate-specific antigen messenger RNA in human prostatic adenocarcinoma cell line LNCaP. Cancer Res., 51: 3748-3752, 1991.
53. Henttu, P., Liao, S., and Vihko, P. Androgens up-regulate the human prostate-specific antigen messenger ribonucleic acid (mRNA), but down-regulate the prostatic acid phosphatase mRNA in the LNCaP cell line. Endocrinology, 130: 766-772, 1992.
54. Kim, I. Y., Kim, J. H., Zelner, D. J., Ahn, H. J., Sensibar, J. A., and Lee, C. Transforming growth factor-β1 is a mediator of androgen-regulated growth arrest in an androgen-responsive prostatic cancer cell line. LNCaP. Endocrinology, 137: 991-999, 1996.
55. Wyllie, A. H., Kerr, J. F. R., and Currie, A. R. Cell death: the significance of apoptosis. Int. Rev. Cytol., 68: 251-306, 1980.
56. Isaacs, J. T. Antagonistic effect of androgen on prostatic cell death. Prostate, 5: 545-557, 1984.
57. Kyprianou, N., English, H. F., and Isaacs, J. T. Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation. Cancer Res., 50: 3748-3753, 1990.
58. Green, M. D., Oturu, E. M., and Tephly, T. R. Stable expression ot a human liver UDP-glucuronosyltransferase (UGT2B15) with activity towards steroids and xenobiotic substrates. Drug Metab. Dispos., 22: 799-805, 1994.
59. Bélanger, G., Beaulieu, M., Marcotte, B., Lévesque, E., Guillemette, C., Hum, D. W., and Bélanger, A. Expression of transcripts encoding steroid UDP-glucuronosyltransferases in human prostate hyperplastic tissue and the LNCaP cell line. Mol. Cell. Endocrinol., 113: 165-173, 1995.
60. Rouault, J. P., Samarut, C., Duret, L., Tessa, C., Samarut, J., and Magaud, J. P. Sequence analysis reveals that the BTG1 anti-proliferative gene is conserved throughout evolution in its coding and 3′ non-coding regions. Gene (Amst.), 129: 303-306, 1993.
61. Kaighn, M. E., Shankar Narayan, K., Ohnuki, Y., Lechner, J. F., and Jones, L. W. Establishment and characterization of a human prostatic carcinoma cell line (PC3). Invest. Urol. 17: 16-23, 1979.
62. Stone, K. R., Mickey, D. D., Wunderli, G. H., and Paulson, D. F. Isolation of a human prostate carcinoma cell line (DU145). Int. J. Cancer, 21: 274-281, 1978.
63. Sanger, F., Nicklen, S., and Coulsen, A. R. DNA sequencing with chain-terminating inhibitors. Proc. Natl. Acad. Sci. USA, 76: 5463-5467, 1977.